Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Integrity™ iCELLis™

Product Image
Product Description

iCELLis™, the world’s first fully integrated high-cell density bioreactor is designed to simplify your process, by combining the advantages of single-use technologies with the benefits of a fixed-bed system. Thanks to its compact design - for a quick implementation and more ease of use – iCELLis represents the new generation single-use bioreactors.

Central to the iCELLis bioreactor technology is the use of a compact fixed-bed, filled with custom macrocarriers. This matrix is made of medical grade polyester microfibers and provides in only 25L volume, up to 500m² growth area available to the cells. This surface is equivalent to the surface of 3000 Roller Bottles (1700cm² each). iCELLis bioreactors are supplied pre-packed with macrocarriers. Compared to standard stirred tank bioreactor using microcarriers, the iCELLis technology leads to a dramatic simplification of cell culture process. It enables to avoid delicate and time consuming manual operations: sterilization and hydration of microcarriers, and bead-to-bead transfers from preculture to final process.

With the biomass multiplication occurring in the fixed-bed, iCELLis bioreactors can be inoculated at very low density. The number and volume of pre-culture steps are reduced considerably: 20 Roller Bottles (1700 cm²) are can be sufficient to inoculate an iCELLis 500 bioreactor (500 m² of available surface to the cells). As a consequence of this process simplification, manual operations and associated costs are reduced dramatically.

Evenly-distributed media circulation is achieved by a built-in magnetic drive impeller, ensuring low shear stress and high cell viability. The cell culture medium flows through the fixed-bed from the bottom to the top. At the top, the medium falls as a thin film down the outer wall where it takes up O2 to maintain high KL.a. in the bioreactor. This unique waterfall oxygenation, together with a gentle agitation and biomass immobilization, enables compact iCELLis to achieve and maintain high-cell densities, equaling the productivity of much larger stirred tank units.

Process simplification, from vial thawing to final product, is at the heart of the iCELLis platform. As cells are immobilized in the fixed-bed and iCELLis operates in perfusion mode, there is no need for centrifugation to harvest the cells, which simplifies further the downstream process. Last but not least, in order to reduce process development time, the perfusion device is integrated into the iCELLis™ skid.

Product Integrity™ iCELLis™
Company ATMI LifeSciences
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

ATMI LifeSciences
10851 Louisiana Avenue South Bloomington, Minnesota 55438 USA

Tel: +1.952.942.0855
Fax: +1.952.516.5465



Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!